Screener
Immunome IMNM Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Payment of offering costs | (364) | (10,485) |
| Proceeds from exercise of stock options | 229 | 213 |
| Net cash (used in) provided by financing activities | (135) | 162,228 |
| Net (decrease) increase in cash and cash equivalents and restricted cash | (70,789) | 114,262 |
| Cash and cash equivalents and restricted cash at beginning of period | 653,692 | 143,451 |
| Cash and cash equivalents and restricted cash at end of period | $582,903 | $257,713 |
| Reconciliation of cash and cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $582,693 | $257,613 |
Item 1. Financial Statements.
FAQ
- What is Immunome's net change in cash?
- Immunome (IMNM) reported net change in cash of -$70.79M in Q1 2026.
- How has Immunome's net change in cash changed year-over-year?
- Immunome's net change in cash decreased by 162.0% year-over-year, from $114.26M to -$70.79M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Immunome's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude